UV1 Vaccine With Pembrolizumab for Patients With Unresectable or Metastatic Melanoma

Summary

UV1 is a therapeutic cancer vaccine that has been explored in prostate and lung cancers, and in combination with ipilimumab in malignant melanoma. This study will explore the safety, tolerability and efficacy of UV1 administered with GM-CSF in melanoma patients who are also receiving pembrolizumab.

Timeline

Start

2018-07-09

Primary completion

2022-10-01

Completion

2024-06-15

Drugs

Indications